Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | DRD1 | P21728 | 2/20 | 0.33 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.31 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.31 |
| ▸ | ESR1 | P03372 | 3/20 | 0.30 |
| ▸ | AR | P10275 | 1/20 | 0.30 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16334652 | 1.00 | NPC1 (0.35) | NPC1DRD1ADORA2AADORA2BMAPT | |
| SCHEMBL16337243 | 0.89 | NPC1 (0.37) | NPC1DRD1ADORA2AADORA2BMAPT | |
| SCHEMBL16819032 | 0.85 | NPC1 (0.36) | NPC1ADORA2AADORA2BMAPTESR2 | |
| SCHEMBL16334500 | 0.84 | NPC1 (0.36) | NPC1DRD1ADORA2AADORA2BMAPT | |
| SCHEMBL16337126 | 0.84 | PKM (0.40) | NPC1DRD1 | |
| SCHEMBL16337670 | 0.78 | DRD1 (0.62) | DRD1 | |
| SCHEMBL22402289 | 0.78 | NPC1 (0.36) | NPC1DRD1MAPT | |
| SCHEMBL16335311 | 0.76 | NPC1 (0.38) | NPC1ADORA2AADORA2BMAPTESR2 | |
| SCHEMBL30864167 | 0.76 | NPC1 (0.35) | NPC1 | |
| SCHEMBL16334924 | 0.76 | NPC1 (0.35) | NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11964961-B2 | Heteroaromatic compounds and their use as dopamine D1 ligands | PFIZER INC. (US) | 2024-04-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11964961-B2 | Heteroaromatic compounds and their use as dopamine D1 ligands | DRD2, DRD1, HTR1D | NPC1 931/4885DRD1 2/4885ADORA2A 377/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.